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respectively. CONCLUSIONS: Self-reported utilization can 
be used to differentiate costs across severity strata in GERD 
sufferers. This information is useful for modeling the economic
consequences of reducing GERD-related severity and may 
be applicable to other conditions when published data are
incomplete.
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OBJECTIVE: Results from studies using patient-reported data
in employed populations indicate that Gastroesophageal Reﬂux
Disease (GERD) causes a reduction in productivity while at work
of around 10%. The aim of this study was to assess if a link
between GERD and reduced productivity while at work can be
established by using objective measurements of hourly and
annual at-work productivity. METHODS: We examined the
Human Capital Management Services Research Reference data-
base of employees where units-of-production are captured on a
per-employee-per-day basis. ICD-9 Codes were used to distin-
guish employees with GERD from the non-GERD cohort. The
index date in the GERD cohort was deﬁned as the date of ﬁrst
diagnosis during 2001 or later, while the average GERD index
date was used in the non-GERD cohort. Hourly and annual 
productivity were measured during the year following each
employee’s index date. Regression modelling was used to
measure the productivity differences between employees with
GERD and employees without GERD while controlling for age,
marital status, race, full-time/part-time status, location, and
comorbidity (Charlson Comorbidity Index). RESULTS: Data
were available for 27,316 employees: 541 employees with GERD
and a control group of 26,775 employees without GERD. The
mean age of employees with GERD was 40 years, and 77% were
full time employees. The analysis of at-work productivity show
that GERD employees’ average units processed were signiﬁcantly
lower by 4.4% hourly and 6.0% annually (P < 0.05). CON-
CLUSIONS: Even though quality aspects of work productivity
are not captured, objective productivity measurements from real
work-output data (the number of units of work performed by
each employee on a daily basis) show that GERD has a signiﬁ-
cant impact on productivity while at work. Interventions focused
on managing GERD could increase work productivity and thus
lead to beneﬁts for the employee, the employer and society as a
whole.
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OBJECTIVES: According to previous data only 30% to 60% of
patients with inﬂammatory bowel disease (IBD) take their med-
ication as prescribed. While objective predictors of nonadherence
are relatively well studied, there is little data regarding what IBD
patients think about their medications and their reasons for non-
adherence. METHODS: A total of 22 consecutive patients with
IBD from the University of Maryland Inﬂammatory Bowel
Disease Program were interviewed. We collected data on the
patients’ sociodemographic proﬁle, their medications, and asked
them to complete the Medication Attitude Survey (MAS). The
MAS has 24 questions asking why patients may incorrectly take
their medications. The nonadherence reasons were identiﬁed
from a literature review. RESULTS: Fifteen patients were female
(68.2%), and the average age was 37.4 ± 13 years. Ten patients
had Crohn’s disease (45.5%), 6 had ulcerative colitis (27.3%),
and 5 had indeterminate colitis (22.7%). Most of the patients
(90.9%) selected at least one reason for nonadherence. The main
reasons (selected by more than 25% of patients) were “I forget
to take my medication”(72.7% of patients), “I feel better”
(40.9%), “My medications are too expensive” and “I feel very
bad”(both 36.6%), “I want to avoid side effects” and “I want
to feel healthy” (both 31.8%), “I want to forget about my
disease” and “I think that the prescribed dose of my medication
is too much” (both 27.3%). The sets of reasons were different
for adherent and nonadherent patients (the degree of nonadher-
ence was assessed using patient self-report). The MAS has shown
good initial psychometric properties with Cronbach Alpha 0.91
and mean inter-item correlations 0.32. CONCLUSIONS: The
identiﬁed reasons for patient nonadherence suggest that patient
education and other interventions are needed to increase 
medication adherence. The scale used in the study can be useful
in routine clinical practice to identify possible problems with
patient adherence.
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OBJECTIVE: The medical literature points out the adherence
and ribavirin dose as important factors to achieve the best results
in the CHC treatment. In Brazil, the government set local assisted
administration centers (LAAC) to provide the drugs and admin-
ister the interferons (conventional and peguilated) to the patients
in order to improve these factors. The objective of this study is
to evaluate the adherence to the CHC treatment with peguin-
terferon and conventional interferon and the actual dose of rib-
avirin administered to the patients, in Brazil. METHODS: Thirty
physicians in south, southwest and Midwest regions of Brazil
performed a prospective cross sectional evaluation. They used a
structured questionnaire with the speciﬁc questions. RESULTS:
A total of 656 patients were evaluated during 2 months. The
average age was 44 years and the mean body weight was 
70.5kg. According to the BMI, 50% of the patients are over-
weight or obese. The adherence to treatment was calculated as
the rate between the prescribed doses and doses actually taken.
79.7% of the patients was 100% adherent. Only 60.8% of the
patients was 100% adherent to conventional interferon. 84.6%
of the patients were 100% adherent to peginterferon alfa 2 a and
86.8% of the patients were 100% adherent to peginterferon 
alfa 2b. LAAC patients adherence (100%) is greater than the
patients that apply the treatment (interferons) at home (84.8%
vs. 71.1%). 93.4% of the Brazilian patients receive 1g per day
or more of ribavirin. Given that the mean weight of the Brazil-
ian patient is 70.5kg the majority of the patients receive more
than 10.6mg/kg of ribavirin. CONCLUSIONS: The median
weight of the Brazilian patients is 70.5kg. More than 90% 
of the patients are receiving 1g per day or more of ribavirin.
LAAC appear to directly affect the adherence to the treatment,
improving it.
